HER1、HER2和HER3表达水平与IRESSA治疗晚期NSCLC疗效和预后的关系(英文)

查看全文 作　　者：Jianming [1]Xu;Emei [1]Gao;Yu [1]Han;Yang [2]Zhang;Suxia [2]Li;Xiaoqing [1]Liu;Zhiqiang [1]Li;Angelo [3]Paradiso 机构地区：[1]Cancer Center, Beijing 307 Hospital, Beijing 100071, China;[2]Cancer Center, The 2nd Affiliated Hospital of Dalian Medical University, Dalian 116027, China;[3]National Cancer Institute, Bari, Italy 出　　处：《The Chinese-German Journal of Clinical Oncology》索引2008年第7卷第8期,共7页 摘　　要：Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum- pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy. 关 键 词：HERl HER2 HER3 表达水平 IRESSA治疗 晚期NSCLC 疗效 预后